BANU K ARUN to Young Adult
This is a "connection" page, showing publications BANU K ARUN has written about Young Adult.
Connection Strength
0.349
-
Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018 02 06; 18(1):152.
Score: 0.040
-
Service Delivery Model and Experiences in a Cancer Genetics Clinic for an Underserved Population. J Health Care Poor Underserved. 2015 Aug; 26(3):784-91.
Score: 0.034
-
Genotype in BRCA-associated breast cancers. Breast J. 2013 Jan-Feb; 19(1):87-91.
Score: 0.028
-
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
Score: 0.026
-
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.
Score: 0.026
-
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53.
Score: 0.026
-
Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009 Feb 15; 115(4):725-30.
Score: 0.022
-
Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk. Pediatrics. 2022 08 01; 150(2).
Score: 0.014
-
Impact of a Genetic Evaluation Initiative to Increase Access to Genetic Services for Adolescent and Young Adults at a Tertiary Cancer Hospital. J Adolesc Young Adult Oncol. 2021 06; 10(3):296-302.
Score: 0.012
-
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 05 10; 38(14):1539-1548.
Score: 0.012
-
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
Score: 0.011
-
Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
Score: 0.010
-
Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):415-423.
Score: 0.010
-
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr Canc Netw. 2017 06; 15(6):797-803.
Score: 0.010
-
Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016 Dec 06; 7(49):80465-80481.
Score: 0.009
-
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2016 06; 157(2):319-327.
Score: 0.009
-
Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 Jan; 155(1):165-73.
Score: 0.009
-
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
Score: 0.008
-
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
Score: 0.008
-
Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
Score: 0.007
-
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
Score: 0.007
-
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
Score: 0.006
-
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov; 124(2):441-51.
Score: 0.006